1. Home
  2. KTTA vs SCNI Comparison

KTTA vs SCNI Comparison

Compare KTTA & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pasithea Therapeutics Corp.

KTTA

Pasithea Therapeutics Corp.

N/A

Current Price

$1.15

Market Cap

5.3M

Sector

Health Care

ML Signal

N/A

SCNI

Scinai Immunotherapeutics Ltd.

N/A

Current Price

$0.87

Market Cap

4.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KTTA
SCNI
Founded
2020
2003
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.3M
4.6M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
KTTA
SCNI
Price
$1.15
$0.87
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
21.7M
50.6K
Earning Date
11-13-2025
11-24-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.26
Revenue
N/A
$1,147,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$3.19
Revenue Growth
N/A
303.87
52 Week Low
$0.28
$0.80
52 Week High
$3.85
$6.18

Technical Indicators

Market Signals
Indicator
KTTA
SCNI
Relative Strength Index (RSI) 59.55 36.37
Support Level $1.10 $0.80
Resistance Level $1.32 $1.26
Average True Range (ATR) 0.18 0.10
MACD 0.00 -0.01
Stochastic Oscillator 11.65 14.57

Price Performance

Historical Comparison
KTTA
SCNI

About KTTA Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

About SCNI Scinai Immunotherapeutics Ltd.

Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.

Share on Social Networks: